4.6 Article

Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+Breast Cancer

Journal

CANCERS
Volume 14, Issue 4, Pages -

Publisher

MDPI
DOI: 10.3390/cancers14041015

Keywords

PDX; BT474; MDA-MB-361; BCM 3472; trastuzumab; [F-18]-FMISO; PET; synergy

Categories

Funding

  1. American Cancer Society
  2. National Cancer Institute [RP170691, NCI-CA125123, R01CA240589]
  3. UAB Comprehensive Cancer Centers Preclinical Imaging Shared Facility [P30CA013148]
  4. [P30 AR048311]
  5. [P30 AI027667]
  6. [RSG-18-006-01-CCE]

Ask authors/readers for more resources

This study investigates the synergistic effect of trastuzumab and radiation therapy in treating HER2-overexpressing breast cancer. It is found that a subtherapeutic dose of trastuzumab sensitizes the tumor microenvironment to fractionated radiation, resulting in a sustained response through innate immune activation, reduced DNA damage repair, and increased tumor oxygenation. The findings suggest that combination therapies can enhance the effectiveness of radiation therapy in HER2-positive breast cancer by modulating the tumor microenvironment.
Simple Summary Trastuzumab and radiation are used clinically to treat HER2-overexpressing breast cancers; however, the mechanistic synergy of anti-HER2 and radiation therapy has not been investigated. In this study, we identify that a subtherapeutic dose of trastuzumab sensitizes the tumor microenvironment to fractionated radiation. This results in longitudinal sustained response by triggering a state of innate immune activation through reduced DNA damage repair and increased tumor oxygenation. As positron emission tomography imaging can be used to longitudinally evaluate changes in tumor hypoxia, synergy of combination therapies is the result of both cellular and molecular changes in the tumor microenvironment. DNA damage repair and tumor hypoxia contribute to intratumoral cellular and molecular heterogeneity and affect radiation response. The goal of this study is to investigate anti-HER2-induced radiosensitization of the tumor microenvironment to enhance fractionated radiotherapy in models of HER2+ breast cancer. This is monitored through in vitro and in vivo studies of phosphorylated gamma-H2AX, [F-18]-fluoromisonidazole (FMISO)-PET, and transcriptomic analysis. In vitro, HER2+ breast cancer cell lines were treated with trastuzumab prior to radiation and DNA double-strand breaks (DSB) were quantified. In vivo, HER2+ human cell line or patient-derived xenograft models were treated with trastuzumab, fractionated radiation, or a combination and monitored longitudinally with [F-18]-FMISO-PET. In vitro DSB analysis revealed that trastuzumab administered prior to fractionated radiation increased DSB. In vivo, trastuzumab prior to fractionated radiation significantly reduced hypoxia, as detected through decreased [F-18]-FMISO SUV, synergistically improving long-term tumor response. Significant changes in IL-2, IFN-gamma, and THBS-4 were observed in combination-treated tumors. Trastuzumab prior to fractionated radiation synergistically increases radiotherapy in vitro and in vivo in HER2+ breast cancer which is independent of anti-HER2 response alone. Modulation of the tumor microenvironment, through increased tumor oxygenation and decreased DNA damage response, can be translated to other cancers with first-line radiation therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available